Could two steroids slash septic shock deaths?
NCT ID NCT07383103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two steroids—hydrocortisone and fludrocortisone—for up to 7 days can lower the risk of death in adults with septic shock. About 336 patients will be randomly assigned to receive either the steroid combo or standard care alone. The main goal is to see if the treatment reduces deaths within 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydrocortisone and fludrocortisone (steroid drugs)
What this could lead to
If it works, this could offer a simple, short-term drug combo to lower death rates in septic shock patients.
What could go wrong
This is a phase 4 trial, so the drugs are already approved, but septic shock is complex and previous steroid studies have had mixed results. Side effects like infections or gastrointestinal issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northern Jiangsu People's Hospital
RECRUITINGYangzhou, Jiangsu, 225000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact